“I'm really proud of the work we are doing with FEMAP,” said Marner. “London has always been close to my heart, and ...

E-Star is developing a platform of Natriuretic Peptides for the treatment of Metabolic Syndrome. The Company's lead asset, MANP, is currently being investigated in a Phase 2 clinical trial. To learn ...

Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system ...

Doheny Eye Institute, one of the nation’s leading vision research institutions, announced that 10 of its ophthalmologists will present their research findings and professional insights during the ...

The FDA Review Division has determined that there does not appear to be a need for an advisory committee meeting at this time for the New Drug Application (NDA) for DCCR (diazoxide choline) ...

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination ...

PharmAla stands ready to support researchers not only with our existing API and 40mg capsules, but in the development of new and novel dosage forms for LaNeo™ MDMA,” said Nicholas Kadysh, CEO, ...

ARLINGTON, Va., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its third quarter and nine-month periods ...

Lyn’s visionary leadership has placed Avalyn at the forefront of respiratory therapeutics, developing groundbreaking inhaled treatments for pulmonary fibrosis. Her strategic prowess, combined with her ...

Curia, a leading contract research, development and manufacturing organization, today announced its commitment to set near- and long-term company-wide greenhouse gas (GHG) emission reductions in line ...

Founded in 2005, the PharmaVoice 100 highlights the driving forces of the life sciences industry who have positively impacted their colleagues, companies and communities. Each honoree is chosen based ...

Among PD-L1 IHC, sTILs and 11 immune signatures analyzed, only DetermaIO was significant for interaction, meaning it could predict which patients were most likely to achieve pathologic complete ...